APS most commonly refers to the Artificial Pancreas System, a technology that automates insulin delivery for people with type 1 diabetes. It connects a glucose sensor, a control algorithm, and an insulin pump into a single loop that adjusts insulin doses in real time, without the person needing to constantly intervene. (If you’re looking for information on antiphospholipid syndrome, a separate autoimmune condition involving blood clotting, see the section at the end of this article.)
How an Artificial Pancreas System Works
Three devices work together to form the system. A continuous glucose monitor (CGM) uses a tiny sensor inserted under the skin to track blood sugar levels every few minutes. That data is sent wirelessly to a control algorithm, which runs on either a smartphone or the insulin pump itself. The algorithm calculates how much insulin is needed and signals the third component, an insulin infusion pump, to deliver small doses throughout the day whenever blood sugar drifts outside the target range.
The term “artificial pancreas” is a bit generous. In a healthy body, the pancreas releases both insulin (to lower blood sugar) and glucagon (to raise it). Most current APS devices only deliver insulin, so they’re technically replacing half the job. That’s why you’ll also see them called hybrid closed-loop systems or automated insulin delivery (AID) systems. “Hybrid” because you still need to tell the system when you’re about to eat and estimate your carbohydrate intake. The system handles the rest, adjusting your baseline insulin dose automatically.
The Algorithm Behind the Decisions
The algorithm is the brain of the system, and different manufacturers use different approaches. Two of the most common are PID control and model predictive control.
A PID algorithm works by reacting to three things at once. The proportional component looks at how far your current glucose is from the target (often set at 120 mg/dL) and delivers insulin in proportion to that gap. The integral component tracks all past deviations, ensuring that persistent drift gets corrected over time. The derivative component watches how fast glucose is changing. If your blood sugar is already heading back toward target, it eases off to prevent overshooting. Every five minutes, the CGM sends a new glucose reading, and the algorithm recalculates a tiny dose called a microbolus.
Model predictive control (MPC) takes a forward-looking approach. Instead of just reacting to what your glucose is doing now, it projects where your blood sugar will be in the near future based on your current levels and how much insulin is still active in your body. If the predicted values are too high, it increases the dose. If they’re trending low, it pulls back. This predictive ability can be especially useful around meals and exercise, when glucose levels change rapidly.
What Results People Actually See
The key metric for APS performance is Time in Range (TIR), the percentage of the day your blood sugar stays between 70 and 180 mg/dL. International guidelines recommend at least 70% TIR. Current systems regularly exceed that threshold. In one study, users who counted carbohydrates precisely before meals achieved an average TIR of about 80%. Even users who simplified their meal announcements, choosing from three preset carbohydrate estimates instead of counting exactly, hit around 73.5% TIR, still above the recommended goal.
For people who previously managed diabetes with a standard insulin pump and sensor (but no automated loop), the jump can be dramatic. Adults who used the automated system more than 50% of the time saw their TIR increase by nearly 30 percentage points over 12 months compared to baseline. Those who used it over 90% of the time saw a 19% increase, likely because they already had better control to begin with.
Open-Source and DIY Systems
Not all artificial pancreas systems come from medical device companies. A dedicated community of people with type 1 diabetes has built open-source alternatives like AndroidAPS and OpenAPS. These use commercially available CGMs and insulin pumps but run custom algorithms on a smartphone or small computer. They emerged years before some commercial options received regulatory approval, driven by the frustration of waiting for industry to catch up.
A 26-week study directly compared one commercial system (Control-IQ) with the open-source AndroidAPS in adults with type 1 diabetes. Both achieved similar Time in Range results: about 86% for the commercial system and 84% for the open-source version, with no significant difference in average blood sugar or long-term glucose control (HbA1c). The commercial system did produce less time spent in hypoglycemia (dangerously low blood sugar). Interestingly, even though participants were mostly satisfied with the commercial system, those who had been using the open-source version didn’t plan to switch. The level of customization and control that open-source systems offer is a major draw for experienced users.
Impact on Daily Life and Stress
Managing type 1 diabetes is mentally exhausting. Every meal, every workout, every unexpected schedule change requires a calculation. One of the most meaningful benefits of an APS is how much of that burden it lifts.
A systematic review and meta-analysis found that adults using automated insulin delivery experienced a significant reduction in diabetes distress. Caregivers, particularly parents of young children with type 1 diabetes, saw an even larger benefit. Parents of younger children gained more relief than parents of teenagers, likely because small children have less predictable eating and activity patterns, making manual management especially stressful. The reduction wasn’t significant for children and teenagers themselves, possibly because the psychological burden of diabetes management falls more heavily on caregivers at younger ages.
If You Searched for Antiphospholipid Syndrome
APS also stands for antiphospholipid syndrome, an autoimmune disorder unrelated to diabetes technology. In this condition, the immune system produces antibodies that attack certain fats in cell membranes, increasing the risk of blood clots in arteries and veins. It’s also a significant cause of pregnancy complications, including recurrent miscarriage.
Diagnosis requires both a clinical event (a confirmed blood clot or pregnancy loss) and positive blood tests for specific antibodies: anticardiolipin antibodies, anti-beta-2-glycoprotein-I antibodies, or lupus anticoagulant. Because these antibodies can appear temporarily during infections, the blood tests must come back positive on two separate occasions at least 12 weeks apart before a diagnosis is confirmed. Antiphospholipid syndrome can occur on its own or alongside other autoimmune conditions like lupus.